Novartis reports nine tumor cases in Zolgensma patients, two linked to vector integration
Novartis confirmed that nine children treated with its SMA gene therapy Zolgensma have been diagnosed with tumors, and in two cases the therapy's viral vector was found integrated into the patients' DNA. The company said the potential risk of tumor formation due to vector integration is already listed in the product label. Over 6,000 patients have received Zolgensma since its 2019 approval, and the reports have prompted regulatory review and a drop in the company’s share price.
Why it matters
Novartis shares fell after the disclosure, reflecting investor concern over a safety issue affecting its flagship, high‑priced therapy (the company’s statement notes the risk is in the label). The confirmed cases may lead to label updates and increased post‑market surveillance, potentially affecting future sales.
Key facts
- 1Novartis reported nine tumor reports in children treated with Zolgensma since its 2019 authorization. biospace.com
- 2Two of the nine cases showed evidence of the therapy's AAV vector integrating into the patients' DNA. biospace.com
- 3More than 6,000 patients worldwide have received Zolgensma since its launch. biospace.com
- 4The therapy is priced at around $2.1 million per treatment. swissinfo.ch
- 5The two confirmed integration cases were observed 18 to 60 months after dosing, according to a parent’s account. techtimes.com
- 6Novartis shares declined on Thursday following the safety disclosure. seekingalpha.com
Summary written by AlphAI AI Desk from 6 of 6 sources. Not investment advice. Figures are as stated by the linked sources.